Vaxcyte, Inc.
(NASDAQ: PCVX)

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.

46.070

-1.630 (-3.42%)
Range 44.790 - 47.510   (6.07%)
Open 47.410
Previous Close 47.700
Bid Price 50.150
Bid Volume 9
Ask Price 52.770
Ask Volume 10
Volume 1,662,320
Value -
Remark
Delayed prices. Updated at 05 Dec 2025 05:00.
Data powered by
View All Events


Loading Chart...

Please login to view stock data and analysis